Table 3.

MSCs-EXOs as miRNAs delivery system in different diseases

MSC-EXOs	Diseases	miRNAs	Route of administration	Explain	References
HUC-MSC- EXOs	Neointimal hyperplasia (NIH)	MiR-148a-3p	Intravenously injected	HUC-MSC-EXOs suppressed NIH in a mouse carotid artery ligation model, and the suppressor properties on VSMC phenotypic switching and migration interceded via transfer of miR-148a-3p to VSMCs to target Serpine1	[142]
UC-MSC- EXOs	Endometrial fibrosis	miR-145-5p/ZEB2	–	This method might reverse endometrial stromal cell fibrosis by controlling miR-145-5p/ZEB2 axis, showing a possible new approach to improve endometrial regeneration	[143]
MSC-EXOs	Renal fibrosis	anti-let-7i-5p	Intravenously injected	Anti-let-7i-5p from MSC-EXOs uses anti-fibrotic efficacy in TGF-β1-stimulated fibrogenic reactions in NRK52E cells in vitro also in the UUO-stimulated renal fibrosis model in vivo by triggering the TSC1/mTOR pathway	[144]
BM-MSC-EXOs	Myocarditis	miR-133	intraperitoneally injected	Increased exosomal miR-133a promoted cardiac action and prevent myocardial fibrosis, and EMT in rats with VMC also improves survival rate and suppresses apoptosis of cardiomyocytes in VMC by targeting MAML1	[175]
BM-MSC-EXOs	Intracerebral hemorrhage (ICH)	miR-146a-5p	Intrastriatal injection	This method could suggest neuroprotection and functional recovery afterward ICH by decreasing neuronal apoptosis and inflammation related to the suppression of microglial M1 polarization via a decrease expression of IRAK1 and NFAT5	[145]